Join
Live feed
·
PRReleasevia Quantisnow
X4 Pharmaceuticals Inc. logo

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

ByQuantisnow·Wall Street's wire, on your screen.
XFOR· X4 Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track XFOR (X4 Pharmaceuticals Inc.) and more on Quantisnow.